<div class="cbioportal-tooltip z-depth-2">
  <div>
    <div class="item" style="
    padding-top: 0;
">
      <div class="col s12 tip-header">
        BRAF V600E in colorectal cancer
      </div>
      <div class="col s12">
        <ul class="tabs" tabs="" style="width: 100%;">
          <li class="tab col s6">
            <div class="" href="#oncogenic" style="
    font-size: 8px;
    line-height: 25px;
">
              <div style="
    color: white;
"><span style="
    font-size: 14px;
    width: 100%;
    float: left;
    line-height: 25px;
">clinical implications</span><span style="
    width: 100%;
    float: left;
    line-height: 25px;
    color: orange;
    font-size: 14px;
">oncogenic</span></div>
            </div>
          </li>
          <li class="tab col s6">
            <div class="" href="#oncogenic" style="
    font-size: 8px;
    line-height: 25px;
">
              <div style="
    color: white;
    opacity: 0.4;
"><span style="
    font-size: 14px;
    width: 100%;
    float: left;
    line-height: 25px;
">Biological Effect</span><span style="
    width: 100%;
    float: left;
    line-height: 25px;
    color: orange;
    font-size: 14px;
">Inactivating</span></div>
            </div>
          </li>
          <div class="indicator" style="right: 0px; left: 0px;"></div>
        </ul>
      </div>
      <div id="oncogenic" class="col s12 tabsContent" style="display: block;margin: 10px 10px 0 10px;">
        BRAF encodes an intracellular kinase and component of the pro-oncogenic MAP-kinase signaling pathway. Mutations of BRAF are found in various cancers, including melanoma and lung cancer. The BRAF V600E mutation is known to be oncogenic.
      </div>
      <div id="mutation-effect" class="col s12 tabsContent" style="display: none;margin: 10px 10px 0 10px;">
        There is level 1 evidence that V600E or V600K mutations in BRAF is associated with response to FDA-approved
        combination of RAF-inhibitor dabrafenib and trametinib in melanoma (PMID: 25287827, 25399551, 25265492), as well
        as dabrafenib monotherapy in non-small cell lung cancer (Planchard, D et al. J Clin. Oncol. abstract 8009;
        2013).
      </div>
    </div>

    <div class="item">
      <table style="
    margin: 0 10px;
    font-size: 13px;
    text-align: center;
" class="bordered">
        <thead>
        <tr>
          <th>Level</th>
          <th>Drug(s)</th>
          <th>Level-associated cancer type(s)</th>
        </tr>
        </thead>
        <tbody>
        <tr>
          <td><img src="resources/images/level-1.png" class="level-1"></td>
          <td>Dabrafenib</td>
          <td>Melanoma</td>
        </tr>
        <tr>
          <td><img src="resources/images/level-1.png" class="level-1"></td>
          <td>Trametinib</td>
          <td>Melanoma</td>
        </tr>
        <tr>
          <td><img src="resources/images/level-1.png" class="level-1"></td>
          <td>Trametinib + Dabrafenib</td>
          <td>Melanoma</td>
        </tr>
        <tr>
          <td><img src="resources/images/level-1.png" class="level-1"></td>
          <td>Vemurafenib</td>
          <td>Melanoma</td>
        </tr>
        <tr>
          <td><img src="resources/images/level-1.png" class="level-1"></td>
          <td>Vemurafenib+Cobimetinib</td>
          <td>Melanoma</td>
        </tr>
        </tbody>
      </table>
    </div>
    <div class="item">
      <p style="
    padding: 0 10px;
"><i style="
    /* padding: 0 10px; */
">The information above is intended for research purposes only and should not be used as a substitute for professional
        diagnosis and treatment.</i></p>
    </div>
    <div class="item-list" style="
    /* padding: 0 10px; */
    padding-top: 10px;
">
      <ul class="collapsible" data-collapsible="accordion" style="margin: 0 10px;">
        <li class="">
          <div class="collapsible-header">Levels<span class="secondary-content"><i style="color: orange"
                                                                                   class="glyphicon glyphicon-chevron-down"></i></span>
          </div>
          <div class="collapsible-body levels" style="display: none;">
            <ul>
              <li><b>Level 1:</b> FDA-approved biomarjer and drug in this indication.</li>
              <li><b>Level 2A:</b> Standard-of-care biomarker and drug in this indication but not FDA-approved.</li>
              <li><b>Level 2B:</b> FDA-approved biomarker and drug in another indication, but not FDA or NCCN
                compendium-listed for this indication.
              </li>
              <li><b>Level 3A:</b> Clinical evidence links biomarker to drug response in this indication but neither
                biomarker or drug are FDA-approved or NCCN compendium-listed.
              </li>
              <li><b>Level 3B:</b> Clinical evidence links biomarker to drug response in another indication but neither
                biomarker or drug are FDA-approved or NCCN compendium-listed.
              </li>
            </ul>
          </div>
        </li>
        <li class="">
          <div class="collapsible-header">Powered by OncoKB(Beta)<span class="secondary-content"><i
            style="color: orange" class="glyphicon glyphicon-chevron-down"></i></span></div>
          <div class="collapsible-body" style="display: none;"><p>OncoKB is under development. To report errors or
            missing annotation about this variant, please send us feedback. For general feedback, please send an email
            to oncokb@cbio.mskcc.org</p></div>
        </li>
      </ul>
    </div>
    <div class="item" style="
    /* display: inline-block; */
     width: 100%;
    padding-top: 0;
    line-height: 40px;
    height: 40px;
">
      <img src="resources/images/oncokb_logo.png" style="
    height: 19px;
    margin-left: 10px;
    margin-top: -4px;
">
      <span class="pull-right" style="margin-right: 10px"><i class="font-size: 12px">Feedback</i></span></div>
  </div>
</div>
